Prelude Therapeutics Incorporated (PRLD)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Prelude Therapeutics Incorporated (PRLD) is up 26.2% since the beginning of the year. At $4 per share, PRLD is trading 33.9% below its 52-week high of $6. Investors who bought $1,000 worth of PRLD shares 5 years ago would now be looking at an investment worth $122.

Prelude Therapeutics Incorporated (PRLD) has returned 26.21% so far this year and 291.32% over the past 12 months.

Based on dividend-adjusted daily data since Sep 25, 2020, PRLD's average daily return is +0.13%, while the average monthly return is +1.14%. At this rate, an investment would double in approximately 5.1 years.

Historically, 41% of months were positive and 59% were negative. The best month was Nov 2023 with a return of +95.9%, while the worst month was Sep 2024 at -60.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.

On a daily basis, PRLD closed higher 47% of trading days. The best single day was Nov 3, 2025 with a return of +150.3%, while the worst single day was Nov 4, 2025 at -55.8%.

Prelude Therapeutics Incorporated has an annualized alpha of 7.90%, beta of 1.51, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since September 28, 2020.

• This stock participated in 125.65% of S&P 500 Index downside but only -30.88% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PRLD ranks 87 for risk / return — in the top 87% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Prelude Therapeutics Incorporated (PRLD) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Prelude Therapeutics Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Prelude Therapeutics Incorporated was 99.33%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Prelude Therapeutics Incorporated drawdown is 96.01%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Prelude Therapeutics Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Prelude Therapeutics Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.